Patent: 10,052,307
✉ Email this page to a colleague
Summary for Patent: 10,052,307
Title: | Micellar nanocomplex |
Abstract: | The present invention relates to micellar nanocomplexes and a method of forming the same. The micellar nanocomplex comprises a micelle and an agent encapsulated within said micelle, where the micelle comprises a polymer-flavonoid conjugate, wherein said polymer is bonded to the B ring of said flavonoid. The micellar nanocomplex may have useful applications as a drug-delivery system. |
Inventor(s): | Kurisawa; Motoichi (Singapore, SG), Nunnarpas; Yongvongsoontorn (Singapore, SG), Ying; Jackie Y (Singapore, SG), Chung; Joo Eun (Singapore, SG), Bae; Ki Hyun (Singspore, SG), Tan; Min-han (Singapore, SG), Lee; Esther (Singapore, SG) |
Assignee: | Agency for Science, Technology and Research (Singapore, SG) |
Application Number: | 15/309,675 |
Patent Claims: | see list of patent claims |
Details for Patent 10,052,307
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | See Plans and Pricing | 2034-05-09 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | See Plans and Pricing | 2034-05-09 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | See Plans and Pricing | 2034-05-09 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | See Plans and Pricing | 2034-05-09 |
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | See Plans and Pricing | 2034-05-09 |
Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | 09/27/2006 | See Plans and Pricing | 2034-05-09 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |